Successful treatment of a Caucasian case of multifocal Castleman’s disease with TAFRO syndrome with a pathophysiology targeted therapy - a case report

Table 2 Laboratory data of the patient

	At the onset of disease	On admission	At 2 months after the onset (before TCZ)	At 3 months after the onset (after TCZ)	At 4 months after the onset (before R-CVP)	At 9 months after the onset (after sixth R-CVP)	At 12 months after the onset
White blood cells (×10 ³ /μL)	11.8	15.9	26.6	12.9	20.9	7.5	8
Hemoglobin (g/dL)	11.5	8.9	6.3	13.2	8	14.7	13.9
MCV (fL)	90.7	85	86	102	92	97.5	97
Platelet counts (×10 ³ /μL)	29	7	11	84	16	295	279
AST (IU/L)	56	104	16	25	19	17	12
ALT (IU/L)	-	67	18	34	71	10	9
LDH (IU/L)	340	637	552	630	824	-	-
Albumin (g/dL)	1.86	1.87	2.2	3	2.4	3.83	3.87
Creatinine (mg/dL)	0.8	1.6	1.3	0.6	0.9	0.6	0.6
Proteinuria (g/24 h)	0.47	1.96	4.52	0.9	1.21	0.1	0
CRP (mg/dL)	22.2	28.3	17.2	0.1	5.1	0.1	0.1
Ferritin (ng/mL)	715	1097	1126	-	1427	294	281
IL6 (pg/mL)	-	19.4	8.8	1.5	2.3	3	1

Reference ranges and abbreviations. White blood cells: 4–10 × 10³/μL; Hemoglobin: 11.5-16 g/dL; MCV (mean corpuscular volume): 80–98 fL; Platelet counts: 150-400 × 10³/μL; AST (aspartate aminotransferase): 0–40 IU/L; ALT (alanine aminotransferase): 0–40 IU/L; LDH (lactate dehydrogenase): 0–450 IU/L; Albumin: 3.7-5.5 g/dL; Creatinine: 0.6-1.4 mg/dL; Proteinuria: < 0.15 g/24 h; CRP (C reactive protein): 0–0.6 mg/dL; Ferritin 12–180 ng/mL; IL6 (interleukin 6): 0-5-2 pg/mL); TCZ: tocilizumab 8 mg/kg; R-CVP: rituximab 375 mg/m³, cyclophosphamide 750 mg/m³, vincristine 1.4 mg/m³ and prednisone 40 mg/m³.

ISSN: 2162-3619